Climb Bio Stock Forecast - Naive Prediction
| CLYM Stock | 5.02 0.11 2.24% |
Climb Stock outlook is based on your current time horizon. Although Climb Bio's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Climb Bio's systematic risk associated with finding meaningful patterns of Climb Bio fundamentals over time.
The RSI of Climb Bio's stock price is about 62 suggesting that the stock is rather overbought by investors as of now. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Climb, making its price go up or down. Momentum 62
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.15) | EPS Estimate Current Year (0.81) | EPS Estimate Next Year (0.81) | Wall Street Target Price 9.5 | EPS Estimate Current Quarter (0.14) |
Using Climb Bio hype-based prediction, you can estimate the value of Climb Bio from the perspective of Climb Bio response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Climb Bio on the next trading day is expected to be 5.67 with a mean absolute deviation of 0.36 and the sum of the absolute errors of 21.78. Climb Bio after-hype prediction price | USD 5.02 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Climb Bio to cross-verify your projections. Climb Bio Additional Predictive Modules
Most predictive techniques to examine Climb price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Climb using various technical indicators. When you analyze Climb charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Climb Bio Cash Forecast
Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Climb Bio's financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 2020-12-31 | Previous Quarter 22.7 M | Current Value 25.8 M | Quarterly Volatility 50.7 M |
Climb Bio Naive Prediction Price Forecast For the 28th of January
Given 90 days horizon, the Naive Prediction forecasted value of Climb Bio on the next trading day is expected to be 5.67 with a mean absolute deviation of 0.36, mean absolute percentage error of 0.19, and the sum of the absolute errors of 21.78.Please note that although there have been many attempts to predict Climb Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Climb Bio's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Climb Bio Stock Forecast Pattern
| Backtest Climb Bio | Climb Bio Price Prediction | Buy or Sell Advice |
Climb Bio Forecasted Value
In the context of forecasting Climb Bio's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Climb Bio's downside and upside margins for the forecasting period are 0.05 and 14.00, respectively. We have considered Climb Bio's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Climb Bio stock data series using in forecasting. Note that when a statistical model is used to represent Climb Bio stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 116.4277 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.357 |
| MAPE | Mean absolute percentage error | 0.1329 |
| SAE | Sum of the absolute errors | 21.7795 |
Predictive Modules for Climb Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Climb Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Climb Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Climb Bio After-Hype Price Density Analysis
As far as predicting the price of Climb Bio at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Climb Bio or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Climb Bio, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Climb Bio Estimiated After-Hype Price Volatility
In the context of predicting Climb Bio's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Climb Bio's historical news coverage. Climb Bio's after-hype downside and upside margins for the prediction period are 0.25 and 13.28, respectively. We have considered Climb Bio's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Climb Bio is very risky at this time. Analysis and calculation of next after-hype price of Climb Bio is based on 3 months time horizon.
Climb Bio Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Climb Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Climb Bio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Climb Bio, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.80 | 8.33 | 0.13 | 0.55 | 4 Events / Month | 6 Events / Month | In about 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
5.02 | 5.02 | 0.00 |
|
Climb Bio Hype Timeline
Climb Bio is currently traded for 5.02. The entity has historical hype elasticity of 0.13, and average elasticity to hype of competition of -0.55. Climb is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is currently at 1.8%. %. The volatility of related hype on Climb Bio is about 2722.22%, with the expected price after the next announcement by competition of 4.47. About 44.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.93. Some equities with similar Price to Book (P/B) outperform the market in the long run. Climb Bio recorded a loss per share of 0.59. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in about 4 days. Check out Historical Fundamental Analysis of Climb Bio to cross-verify your projections.Climb Bio Related Hype Analysis
Having access to credible news sources related to Climb Bio's direct competition is more important than ever and may enhance your ability to predict Climb Bio's future price movements. Getting to know how Climb Bio's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Climb Bio may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ENTX | Entera Bio | 0.04 | 7 per month | 0.00 | (0.13) | 8.57 | (8.05) | 22.41 | |
| SPRO | Spero Therapeutics | (0.04) | 9 per month | 2.67 | 0 | 3.64 | (5.04) | 13.07 | |
| MCRB | Seres Therapeutics | (1.12) | 9 per month | 0.00 | (0.02) | 9.13 | (7.64) | 54.10 | |
| ANIX | Anixa Biosciences | (1.42) | 10 per month | 0.00 | (0.06) | 8.98 | (6.51) | 40.89 | |
| ABOS | Acumen Pharmaceuticals | 0.04 | 8 per month | 4.54 | 0.02 | 9.94 | (7.18) | 25.06 | |
| INO | Inovio Pharmaceuticals | (0.17) | 9 per month | 0.00 | (0.11) | 6.87 | (6.80) | 36.52 | |
| ACTU | Actuate Therapeutics Common | (0.61) | 5 per month | 0.00 | (0.12) | 5.40 | (6.74) | 20.01 | |
| TTRX | Turn Therapeutics Common | 0.12 | 2 per month | 7.17 | 0.03 | 18.15 | (11.81) | 42.47 | |
| VTGN | VistaGen Therapeutics | (0.01) | 6 per month | 0.00 | (0.14) | 7.61 | (12.80) | 96.59 | |
| AGEN | Agenus Inc | 0.11 | 9 per month | 0.00 | (0.11) | 6.63 | (6.79) | 30.06 |
Other Forecasting Options for Climb Bio
For every potential investor in Climb, whether a beginner or expert, Climb Bio's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Climb Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Climb. Basic forecasting techniques help filter out the noise by identifying Climb Bio's price trends.Climb Bio Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Climb Bio stock to make a market-neutral strategy. Peer analysis of Climb Bio could also be used in its relative valuation, which is a method of valuing Climb Bio by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Climb Bio Market Strength Events
Market strength indicators help investors to evaluate how Climb Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Climb Bio shares will generate the highest return on investment. By undertsting and applying Climb Bio stock market strength indicators, traders can identify Climb Bio entry and exit signals to maximize returns.
Climb Bio Risk Indicators
The analysis of Climb Bio's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Climb Bio's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting climb stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.86 | |||
| Semi Deviation | 5.14 | |||
| Standard Deviation | 8.11 | |||
| Variance | 65.73 | |||
| Downside Variance | 31.67 | |||
| Semi Variance | 26.46 | |||
| Expected Short fall | (7.51) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Climb Bio
The number of cover stories for Climb Bio depends on current market conditions and Climb Bio's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Climb Bio is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Climb Bio's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Climb Bio Short Properties
Climb Bio's future price predictability will typically decrease when Climb Bio's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Climb Bio often depends not only on the future outlook of the potential Climb Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Climb Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.2 M | |
| Cash And Short Term Investments | 150.9 M |
Check out Historical Fundamental Analysis of Climb Bio to cross-verify your projections. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.